Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 61 to 61 of 61 entries
Sorted by: Best Match Show Resources per page
Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B cell malignancies.

Molecular oncology

Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS.
PMID: 34861096
Mol Oncol. 2021 Dec 03; doi: 10.1002/1878-0261.13153. Epub 2021 Dec 03.

Most patients with chronic lymphocytic leukemia (CLL) initially respond to targeted therapies, but eventually relapse and develop resistance. Novel treatment strategies are therefore needed to improve patient outcomes. Here, we performed direct drug testing on primary CLL cells and...

Cite
Melvold K, Giliberto M, Karlsen L, et al. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B cell malignancies. Mol Oncol. 2021;doi: 10.1002/1878-0261.13153.
Melvold, K., Giliberto, M., Karlsen, L., Ayuda-Durán, P., Hanes, R., Holien, T., Enserink, J., Brown, J. R., Tjønnfjord, G. E., Taskén, K., & Skånland, S. S. (2021). Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B cell malignancies. Molecular oncology, . https://doi.org/10.1002/1878-0261.13153
Melvold, Katrine, et al. "Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B cell malignancies." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13153
Melvold K, Giliberto M, Karlsen L, Ayuda-Durán P, Hanes R, Holien T, Enserink J, Brown JR, Tjønnfjord GE, Taskén K, Skånland SS. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B cell malignancies. Mol Oncol. 2021 Dec 03; doi: 10.1002/1878-0261.13153. Epub 2021 Dec 03. PMID: 34861096.
Copy Download .nbib Format: NLM
Showing 61 to 61 of 61 entries